Marker Therapeut SEC Filings

Marker Therapeutics, Inc. (MRKR) reported that director Norman David Eansor received new stock option awards. On 11/17/2025, he was granted options to purchase 84,411 shares of common stock at an exercise price of $0.9548 per share under the company’s 2020 Omnibus Stock Ownership Plan, representing the remaining options for his service as a director for 2024. These options vest on the anniversary of the grant date and expire on 11/17/2035.

On the same date, he was also granted options to purchase an additional 137,330 shares of common stock at an exercise price of $0.9548 per share for his service as a director for 2025. These options have the same vesting schedule and expiration date of 11/17/2035 and are held as direct ownership.

Marker Therapeutics director Steve Elms reported new stock option awards for board service. On 11/17/2025, he received stock options to buy 84,411 shares of common stock at an exercise price of $0.9548, representing remaining options for his 2024 director compensation under the 2020 Omnibus Stock Ownership Plan; 30,000 shares had previously been granted on February 12, 2025. On the same date, he also received options for 137,330 shares for his 2025 director service, also at $0.9548 per share. Both grants vest on the anniversary of the grant date and expire on 11/17/2035, and are held as direct ownership.

Marker Therapeutics filed a Form 8-K to report its financial results for the third quarter ended September 30, 2025, and to provide recent corporate updates. The company furnished a press release as Exhibit 99.1, which is incorporated by reference.

The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act or Securities Act, limiting associated liabilities. The filing lists the company’s common stock trading under MRKR on The Nasdaq Stock Market and was signed by President and CEO Juan Vera.

Marker Therapeutics (MRKR) filed its Q3 2025 10‑Q, reporting cash, cash equivalents and restricted cash of $18.9M as of September 30, 2025 and total assets of $21.7M. The quarter showed grant income of $1.23M, research and development expense of $2.35M and general and administrative expense of $1.02M, resulting in a Q3 net loss of $2.0M (basic and diluted EPS $0.12 loss).

For the nine months, grant income was $2.44M and operating expenses totaled $13.45M, including a $0.45M loss on early termination of a vendor agreement, leading to a year‑to‑date net loss of $10.46M. The company raised liquidity via ATM sales, issuing 1,624,075 shares for net proceeds of $4.5M between July 17–21, 2025 and 3,734,217 shares for net proceeds of $5.4M on August 26, 2025. Shares outstanding were 16,673,127 as of November 6, 2025.

Management states there is “substantial doubt” about the ability to continue as a going concern, though current resources are expected to fund operations through the third quarter of 2026. The company continues to advance MT‑601 manufacturing via a Cellipont SOW and reports multiple active grants, including CPRIT programs with $1.4M recorded as restricted cash and deferred revenue.

Marker Therapeutics (MRKR) appointed Kathryn Penkus Corzo to its Board, effective November 1, 2025. The Board also approved equity awards under the 2020 Equity Incentive Plan.

Ms. Corzo received 147,611 stock options at fair market value, vesting evenly over 36 months, tied to continued Board service. Separately, CEO Dr. Juan Vera was granted 250,000 stock options at fair market value, vesting annually over four years. The company noted no arrangements leading to Ms. Corzo’s selection and no related party transactions, and she will stand for re‑election at the next annual meeting.

Marker Therapeutics (MRKR) filed a Form 4 reporting a director stock option grant. The filing shows a stock option (right to buy) for 147,611 shares at an exercise price of $0.9877, granted on 10/31/2025 under the company’s 2020 Omnibus Stock Ownership Plan. The options vest in 36 equal monthly installments, subject to continued board service, and expire on 10/31/2035. Following the transaction, 147,611 derivative securities are beneficially owned, held directly.

Marker Therapeutics (MRKR)employee stock option grant for 250,000 shares at an exercise price of $0.9877 per share on October 31, 2025.

Per the plan terms, 25% vests on the first anniversary of the grant date, with the balance vesting in equal annual installments over the next three years, contingent on continued service. The options expire on October 31, 2035.

Marker Therapeutics (MRKR) filed a Form 3 reporting the initial beneficial ownership for a director as of 10/31/2025. The filing states that no securities are beneficially owned.

The form was signed by /s/ Julio C. Esquivel as attorney-in-fact for Kathryn Penkus Corzo, pursuant to a power of attorney dated October 15, 2025.